Markets
Stock Market Floor
(Angela Weiss/Getty Images)

Robinhood results to shed light on volatile quarter

The stock plunged nearly 50% during the market rout before bouncing over 40% after Trump’s tariff pause.

Matt Phillips

Stock and crypto brokerage app Robinhood Markets is on the docket for earnings Wednesday after the close. (Sherwood Media is an editorially independent subsidiary of Robinhood Markets Inc.)

The first quarter was a volatile one for the company. In February, it reported strong Q4 results that sent shares to a post-IPO high of more than $65 on Valentine’s Day. A few days later, the tariff-related sell-off for stocks and crypto began, with no reprieve for HOOD.

Between February 14 and April 8 — the day before President Trump announced a “pause” on tariffs — Robinhood plunged nearly 50%. Then came the April 9 tariff pause, which catapulted the stock back up, along with the broader markets.

The hive mind of sell-side analysts expects the company to report $0.33 a share on revenues of $920 million. Those expectations have seen a major reduction, more than 20% off the highs hit in the immediate aftermath of February earnings. Over the same period, profit estimates for the S&P 500 as a whole came under the knife by less than 2%.

Of course, the reaction of the stock Wednesday could be cued by the color of trading activity at Robinhood so far this month, per JPMorgan analysts.

“We expect positive commentary around the robust activity in early April as retail was often cited as net buyers in the first week post-U.S. tariff announcements,” they wrote in a note Tuesday.

Disappointing such expectations can result in jarring moves for shares.

Interactive Brokers dove 9% on April 16, after it reported results, and executives told analysts that they’d seen a decline in margin loans in early April.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.